Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study
| Autor: | Martin Rickenbach, Bernard Hirschel, Amalio Telenti, Rainer Weber, Enos Bernasconi, Markus Flepp, Jean-Philippe Chave, Hansjakob Furrer, Karim Boubaker, Milos Opravil, Cornelia Junghans, Alexander Haensel, Katia Boggian |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male medicine.medical_specialty HIV Infections/ drug therapy Lipodystrophy Anti-HIV Agents HIV Infections Lipodystrophy/ chemically induced Body Mass Index Fats Acquired immunodeficiency syndrome (AIDS) Abacavir Immunopathology Internal medicine medicine Humans Anti-HIV Agents/ adverse effects Pharmacology (medical) Prospective Studies Sida Aged ddc:616 Fats/metabolism Reverse-transcriptase inhibitor biology business.industry Stavudine Middle Aged medicine.disease biology.organism_classification Stavudine/adverse effects Infectious Diseases Cross-Sectional Studies Logistic Models Immunology Female business Cohort study medicine.drug |
| Zdroj: | Journal of Acquired Immune Deficiency Syndromes, Vol. 31, No 1 (2002) pp. 50-55 |
| ISSN: | 1525-4135 |
| Popis: | We prospectively assessed the 1-month prevalence of abnormal body fat distribution in HIV-infected individuals. Of 1,359 patients treated with antiretroviral drugs, 578 (43%) had signs of abnormal fat distribution. Peripheral fat loss was observed in 382 patients (28%), whereas 412 (30%) had signs of fat accumulation. The presence of lipodystrophy (peripheral fat loss with or without fat accumulation) was found to be independently associated with increasing age (less than 35 years of age as a reference group: 35 to 41 years of age, OR = 1.5 [95% CI, 1.1-2.3]; and older than 41 years of age, OR = 2.4 [95% CI, 1.7-3.5]), current use of stavudine (OR = 2.4 [95% CI, 1.8-3.3]), current use of abacavir (OR = 2.1 [95% CI, 1.3-3.4]), and elevated lactate level (OR = 1.6 [95% CI, 1.1-2.4]). The prevalence of lipodystrophy was higher among patients who had received stavudine for a longer period (no stavudine in the current combination as a reference group: 24 months, OR = 3.2 [95% CI, 2.4-4.3]). This study confirms the association between the use of stavudine and lipodystrophy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|